OREXIGEN THERAPUTCS (NASDAQ:OREX)
6.87
0.23 (3.24%)
| OREXIGEN THERAPUTCS (NASDAQ:OREX) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $7.10 | 52 Week High | $10.83 | ||
| Open | $7.05 | 52 Week Low | $1.55 | ||
| Day High | $7.21 | P/E | N/A | ||
| Day Low | $6.82 | EPS | $-2.04 | ||
| Volume | 943,050 | ||||
| More OREX Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| HWAY | 3 | PALM | 3 |
| SNX | 3 | APOL | 2 |
| IART | 2 | AFFX | 2 |
| ARG | 2 | HEB | 2 |
| QCOM | 2 | COH | 2 |
| RRD | 2 | HGSI | 2 |
Entities who have mentioned OREX
- Jefferies & Co | View Related Stories »
- Bankruptcy | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Dividend | View Related Stories »
- SAC Capital | View Related Stories »
- Steven A. Cohen | View Related Stories »
- Citi | View Related Stories »
- Morgan Stanley | View Related Stories »
- Morgan Joseph | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Crude Oil | View Related Stories »
- 13G | View Related Stories »
- After-Hours Movers | View Related Stories »
- Roth Capital | View Related Stories »
- Rodman & Renshaw | View Related Stories »
- Deutsche Bank | View Related Stories »
- BMO Capital | View Related Stories »
- Warren Buffett | View Related Stories »
- S3 | View Related Stories »
- Canaccord Adams | View Related Stories »
- JMP Securities | View Related Stories »
- Morgan Keegan & Company | View Related Stories »
- Fidelity Investments | View Related Stories »
- ADP Employment Report | View Related Stories »
- Federal Open Market Committee | View Related Stories »
View All Major News StreetInsider.com Major News for OREX
- Orexigen (OREX) Reports Q3 Loss of $0.33, Beats by 3c
- Orexigen Therapeutics (OREX) Tops Q4 View By 5c
View All ReportsStreetInsider.com Reports on OREX
- Orexigen (OREX) Reports Q3 Loss of $0.33, Beats by 3c
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Orexigen Therapeutics (OREX) Announces Statistically Significantly Phase 2b Trial for Empatic
- Orexigen Therapeutics (OREX) Schedules September 30, 2009 Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic
- Orexigen Therapeutics (OREX) Files $150M Mixed Securities Shelf
View All Press ReleasesCompany Press Releases on OREX
- Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
- Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
- Orexigen(R) Therapeutics Schedules November 4, 2009 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2009
- Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
- Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
StreetInsider Reports on OREX by Category
View All BlogsBlogs on OREX
- Amylin Takes Lead in Obesity Race
- Don't Expect Amylin to Eat the Obesity Market's Lunch
- 19 'Babies with Bathwater' and 1 'Dog with Fleas' Stocks for the Week
- FDA Calendar Extreme Trades: 85 Single Digit Stocks
- Cramer's Mad Money - Hard Times, Beer and Casinos (10/2/09)
View All FilingsSEC Filings on OREX
- Form 4 Orexigen Therapeutics, For: Nov 16 Filed by: DUNAYEVICH EDUARDO
- Form 4 Orexigen Therapeutics, For: Nov 12 Filed by: VITULLO NICOLE
- Form 4 Orexigen Therapeutics, For: Nov 12 Filed by: Halak Brian K
- Form 4 Orexigen Therapeutics, For: Nov 12 Filed by: SCHOEMAKER KATHLEEN K
- Form 4 Orexigen Therapeutics, For: Nov 12 Filed by: TREU JESSE I
Comments on OREX
No comments are currently available.
